Head-to-head evidence
MP-513 vs Yogliptin
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Type 2 Diabetes
Shared mechanism: DPP-4 · full Type 2 Diabetes pipeline
MP-513
Developed by Mitsubishi Tanabe Pharma
NCT00974090 · Phase 3 · completed
This was a randomized, quadruple-blind, placebo-controlled Phase 3 study of 194 adults with type 2 diabetes inadequately controlled on sulfonylurea therapy, with a 12-week double-blind period followed by a 40-week open-label extension. The primary endpoint - change from baseline in HbA1c at Week 12 - is a hard, regulator-accepted measure of glycemic control, and the comparison clearly favored teneligliptin (LS mean -0.71% vs +0.29% for placebo, SE 0.06 per arm), however statistical significance is not reported.
Yogliptin
Developed by Chengdu Easton Biopharmaceuticals
NCT05318326 · Phase 3 · status unknown
The trial randomly assigns patients to Yogliptin or a matching placebo and blinds patients, care providers, investigators and outcome assessors alike, using HbA1c change, the standard regulator-accepted measure for diabetes drugs, as its main result. Results have not been posted yet, so whether Yogliptin lowered blood sugar significantly more than placebo is not yet known.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: MP-513's landscape · Yogliptin's landscape